Pfizer is looking to sell its remaining stake in Covid-19 vaccine partner BioNTech. Have the good days finally come to an end ...
A significant development emerged on November 13 when Pfizer announced it had sold 54.7% of its stake in BioNTech, retaining only $163.5 million worth of shares. This move marks a substantial shift in ...
BioNTech formally launched its public takeover bid on October 22, 2025, offering CureVac shareholders approximately $5.46 per share in BioNTech American Depositary Shares. The exchange ratio includes ...
SC lawmakers advanced a bill that would require a disclaimer for COVID-19 vaccinations. Physicians have broadly encouraged ...
The German biopharmaceutical company BioNTech finds itself at a critical juncture following a significant divestment by its ...
Arturo Bris, IMD professor in geopolitics and business, examines Europe’s often-overlooked innovation engine, unpacking why ...
BioNTech faces a pivotal moment in its corporate evolution as two major developments converge, testing the company's strategic direction and market confidenc ...
At the conference, Acuitas' Chief Scientific Officer, Dr. Ying Tam, showcased the company's Next-Generation LNP advancements, a comprehensive approach that uses multiple technologies and strategies to ...
Pfizer has sold a significant portion of its stake in German drugmaker BioNTech SE, a more than five years after the two ...
Pfizer sell 508M stake in BioNTech through an overnight block trade, marking its exit from the COVID-19 vaccine partner's equity.
A BioNTech spokesperson downplayed the news, insisting that the two companies remain “close” and have a “strong collaboration ...
Pfizer Inc said on Thursday it sold a part of its stake in German drugmaker BioNTech SE , more than five years after both ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback